Weiss Amir 4

What Happened

• Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries Ltd. (TEVA), had 3,537 restricted share units convert/exercise on March 5, 2026. The filing shows an acquisition/conversion of 3,537 shares and a simultaneous disposition of 3,537 shares at $0.00, resulting in no cash proceeds reported.
• This was a compensation-related vesting/conversion event (not an open-market buy or sell). Such transactions are typically routine — converting vested RSUs and immediately surrendering shares (often to satisfy tax withholding or as a cash-settlement alternative).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely within SEC two-business-day window).
• Reported amounts: 3,537 shares converted/exercised; 3,537 shares disposed at $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note:
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
  • F2: Each restricted share unit (RSU) represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.
  • F3: The RSUs were granted March 5, 2025; 3,537 vested on March 5, 2026 (with further vesting in later years per schedule).
• Transaction code M = exercise or conversion of a derivative security.

Context

• The filing indicates an RSU vesting/conversion and immediate surrender/disposition of the same number of shares. That pattern commonly reflects shares withheld by the company to cover taxes or a cash-settlement choice by the company/committee; the Form 4 does not state the precise mechanism here.
• This is a compensation/vesting event rather than a market trade, so it does not necessarily signal the insider’s view on the company’s stock.